Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients With Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-0560
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)